Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Benzamides (13):
Recent article
Benzamides
Abstract
We show that two PARP1 inhibitors, PJ-34 and 3-AB, attenuate AKT phosphorylation at serine 473 (S473) independent of DNA repair impairment. These inhibitors decrease the AKT-associated phosphorylation of FOXO3A, enhance the nuclear retention of FOXO3A, and activate its transcriptional activity. We f...
|
PMID: 21821012
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Organic Letters (13)6 2011
Abstract
An efficient copper-catalyzed approach to quinazolinone derivatives has been developed, and the protocol uses cheap and readily available substituted 2-halobenzamides and (aryl)methanamines as the starting materials as well as economical and environmentally friendly air as the oxidan...
|
PMID: 21344914
PDF is available here.
PDF is available here.
Abstract
ACS Chemical Biology (5)11 2010
Abstract
We describe the identification of a synthetic RORα/RORγ ligand, SR1078. SR1078 modulates the conformation of RORγ in a biochemical assay and activates RORα and RORγ driven transcription. Furthermore, SR1078 stimulates expression of endogenous ROR target genes in HepG2 cells that express both RO...
|
PMID: 20735016
PDF is available here.
PDF is available here.
Cancer Science (101)11 2010
Abstract
We identified an SP in the HL cell lines, KMH2 and L428. This SP almost entirely consists of distinct small mononuclear cells, whereas the non-SP is a mixture of relatively large cells with H or RS cell-like morphology. Culture of the small mononuclear cells in the SP from KMH2 generated a non-SP. S...
|
PMID: 20735433
PDF is available here.
PDF is available here.
Abstract
Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure. Arginine vasopressin, the native V2 recep...
|
PMID: 21046526
PDF is available here.
PDF is available here.
Abstract
A novel synthesis of 4-[(18)F]fluorobenzylamine ([(18)F]FBA) by means of transition metal-assisted sodium borohydride reduction of 4-[(18)F]fluorobenzonitrile ([(18)F]FBN) is described. This approach could successfully be extended to borohydride exchange resin (BER) enabling a viable option for use...
|
PMID: 20740244
PDF is available here.
PDF is available here.
Abstract
Chronic obstructive pulmonary disease (COPD) is associated with substantial morbidity and mortality and is characterised by persistent airway inflammation, which leads to impaired airway function, quality of life and intermittent exacerbations. In spite of recent advances in the treatment of COP...
|
PMID: 20887341
PDF is available here.
PDF is available here.
Abstract
These results suggest that under the conditions in which URB597 promotes extinction (e.g., Manwell et al. (2009)) it does not interfere with drug-induced reinstatement of either conditioned floor preference or avoidance. That is, although activation of the endocannabinoid (eCB) system promotes extin...
|
PMID: 20643159
PDF is available here.
PDF is available here.
Abstract
Abstract
We have examined the effects of the dual antidepressant, venlafaxine, on 5-HT(4) receptor-mediated signalling events.
The effects of 21 days treatment (p.o.) with high (40 mg·kg(-1)) and low (10 mg·kg(-1)) doses of venlafaxine, were evaluated at different levels of 5-HT(4) receptor-mediated ne...
|
PMID: 20880406
PDF is available here.
PDF is available here.
Abstract
We now show that, whereas blockade of either the extracellular signal-regulated kinase (ERK) pathway or the phosphatidylinositol 3-kinase (PI3K)-Akt pathway alone induced only a low level of cell death, it markedly sensitized NSCLC or CML cells to the induction of apoptosis by histone deacetylase (H...
|
PMID: 20026060
PDF is available here.
PDF is available here.
Behavioural Pharmacology (21)5-6 2010
Abstract
We investigated the effects of a selective glycine transporter-1 inhibitor, SSR504734, on contextual fear conditioning. In a fear acquisition experiment, rats were administered SSR504734 (3-30 mg/kg, intraperitoneal) 1 h before fear conditioning (i.e. inescapable footshock). Twenty-four hours after...
|
PMID: 20613495
PDF is available here.
PDF is available here.
Abstract
We investigated the role of the prenylation transferases in the regulation of the cytoskeletal organization and motility of PC-3 prostate cancer cells. This was done by using FTI-277, GGTI-298 or NE-10790, the specific inhibitors of FTase (farnesyltransferase), GGTase (geranylgeranyltransferase)-I a...
|
PMID: 20446922
PDF is available here.
PDF is available here.
Abstract
We found that higher levels of trait impulsivity were predicted by diminished midbrain D2/D3 autoreceptor binding and greater amphetamine-induced DA release in the striatum, which was in turn associated with stimulant craving. Path analysis confirmed that the impact of decreased midbrain D2/D3 autor...
|
PMID: 20671181
PDF is available here.
PDF is available here.
Abstract
Journal of Molecular Biology (400)4 2010
Abstract
We report the structure of the FAAH-URB597 complex at 2.3 A resolution. The structure provides insights into mechanistic details of enzyme inactivation and experimental evidence of a previously uncharacterized active site water molecule that likely is involved in substrate deacylation. This water mo...
|
PMID: 20493882
PDF is available here.
PDF is available here.
Cell Cycle (9)14 2010
Abstract
We present the novel chemical entity FM19G11, a new modulator of HIF1alpha expression, which was used as a molecular tool to dissect and further characterize the cross-talk between these signaling cascades in human colon carcinoma cell lines. To our knowledge, FM19G11 is the first drug that triggers...
|
PMID: 20676050
PDF is available here.
PDF is available here.
Abstract
We tested the effects of PD0325901 on PTC cells harboring either mutation in vitro by growth curves and Western blots and in vivo using a murine orthotopic xenograft model. We found that 50% growth inhibition (GI(50)) by PD0325901 was 11 nmol/L for the PTC cells with the RET/PTC1 rearrangement and 6...
|
PMID: 20587665
PDF is available here.
PDF is available here.
Addiction Biology (15)3 2010
Abstract
We investigated whether the dopamine D3 partial agonist CJB090 (1-10 mg/kg, i.v) and the D3 antagonist PG01037 (8-32 mg/kg, s.c.) modified methamphetamine (0.05 mg/kg/injection) intravenous self-administration under fixed- (FR) and progressive- (PR) ratio schedules in rats allowed limited (short acc...
|
PMID: 20456290
PDF is available here.
PDF is available here.
Abstract
We show that DNA demethylation in the mouse PGCs is mechanistically linked to the appearance of single-stranded DNA (ssDNA) breaks and the activation of the base excision repair (BER) pathway, as is the case in the zygote where the paternal pronucleus undergoes active DNA demethylation shortly after...
|
PMID: 20595612
PDF is available here.
PDF is available here.
Abstract
The mechanisms responsible for anti-arrhythmic protection during ischemia-reperfusion (IR) in exercised hearts are not fully understood. The purpose of this investigation was to examine whether the ATP-sensitive potassium channels in the mitochondria (mito K(ATP)) and sarcolemma (sarc K(ATP)) provid...
|
PMID: 20435852
PDF is available here.
PDF is available here.
Abstract
Roflumilast, a new inhibitor of phosphodiesterase 4, showed moderate efficacy in clinical trials with patients suffering from chonic obstructive pulmonary disease (COPD). Improvement of pulmonary function is predominantly attributed to antiinflammatory effects with decrease in mucus secretion and le...
|
PMID: 20687460
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.
Cancer Research (70)13 2010
Abstract
We corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAF(V600E) in melanoma cell lines and tumor diges...
|
PMID: 20551059
PDF is available here.
PDF is available here.